Cancer Family
Skin Neoplasm
CI-CAN-00000051Explore in graph →
Non-malignant346 active trials14 approved drugs74 evidence items
Loading cancer entity…
Cancer Family
CI-CAN-00000051Explore in graph →
Clinical trials
1,424 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03380026 | Mechlorethamine Induced Contact Dermatitis Avoidance Study(MIDAS) | completed | Phase 2 | 28 | Rochester Skin Lymphoma Medical Group, PLLCOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03409432 | Brentuximab Vedotin and Lenalidomide in Treating Patients With Stage IB-IVB Relapsed or Refractory T-Cell Lymphoma | completed | Phase 2 | 26 | John ReneauOTHER | 1 | Aug 13, 2026 | clinicaltrials |
| NCT02581930 | Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma | completed | Phase 2 | 18 | National Cancer Institute (NCI)NIH | 1 | Aug 11, 2026 | clinicaltrials |
| NCT01708941 | Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Jul 21, 2026 | clinicaltrials |
| NCT07671495 | Adjuvant Therapy of Skin Melanoma With Alpha Interferon and Naderin(ATSMAIN) | completed | Phase 2 | 278 | MIPO ClinicOTHER | 0 | Jun 30, 2026 | clinicaltrials |
| NCT04552990 | Use of Jet-injection in Photodynamic Therapy for Basal Cell Carcinoma | completed | Phase 2 | 16 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT02180867 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | completed | Phase 2 / Phase 3 | 140 | National Cancer Institute (NCI)NIH | 3 | Jun 17, 2026 | clinicaltrials |
| NCT02232516 | Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma | completed | Phase 2 | 30 | Northwestern UniversityOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT02799485 | sEphB4-HSA in Treating Patients With Kaposi Sarcoma | completed | Phase 2 | 23 | AIDS Malignancy ConsortiumNETWORK | 1 | Jun 1, 2026 | clinicaltrials |
| NCT06608238 | Phase 2 Study Evaluating the Safety and Efficacy of Microneedle-mediated Delivery of Doxorubicin (D-MNA) in Patients With Nodular Basal Cell Carcinoma. | completed | Phase 2 | 90 | SkinJect, Inc.INDUSTRY | 2 | May 4, 2026 | clinicaltrials |
| NCT03574792 | Gabapentin, Methadone, and Oxycodone With or Without Venlafaxine Hydrochloride in Managing Pain in Participants With Stage II-IV Squamous Cell Head and Neck Cancer Undergoing Chemoradiation Therapy | completed | Phase 2 | 62 | Roswell Park Cancer InstituteOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT01384513 | A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies | completed | Phase 2 | 40 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT03601806 | Pomalidomide in Treating Patients With Kaposi Sarcoma and Human Immunodeficiency Virus Infection | completed | Phase 2 | 26 | AIDS Malignancy ConsortiumNETWORK | 3 | Apr 13, 2026 | clinicaltrials |
| NCT03620019 | Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | completed | Phase 2 | 25 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Mar 27, 2026 | clinicaltrials |
| NCT06036836 | Study of Favezelimab Coformulated With Pembrolizumab (MK-4280A) in Participants With Selected Solid Tumors (MK-4280A-010) | completed | Phase 2 | 163 | Merck Sharp & Dohme LLCINDUSTRY | 10 | Mar 19, 2026 | clinicaltrials |
| NCT02213913 | Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas | completed | Phase 1 / Phase 2 | 55 | University of ChicagoOTHER | 1 | Mar 11, 2026 | clinicaltrials |
| NCT05005845 | NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) | completed | Phase 2 | 199 | NFlection Therapeutics, Inc.INDUSTRY | 1 | Feb 17, 2026 | clinicaltrials |
| NCT05872854 | Treatment of Mycosis Fungoides With Hypericin Ointment and Visible Light(RW-HPN-MF-01) | completed | Phase 2 | 10 | Ellen Kim, MDOTHER | 1 | Feb 9, 2026 | clinicaltrials |
| NCT03082534 | Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma | completed | Phase 2 | 78 | University of California, San DiegoOTHER | 1 | Jan 28, 2026 | clinicaltrials |
| NCT02636569 | Topical Chemoprevention of Skin Cancer Biomarkers | completed | Phase 2 | 24 | University of Alabama at BirminghamOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT00975819 | Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies | completed | Phase 2 | 61 | Denise Martin AdamsOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT04154943 | Study of Cemiplimab in Patients With Type of Skin Cancer Stage II to IV Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 79 | Regeneron PharmaceuticalsINDUSTRY | 3 | Dec 23, 2025 | clinicaltrials |
| NCT03077451 | Nelfinavir Mesylate in Treating Patients With Kaposi Sarcoma | completed | Phase 2 | 36 | AIDS Malignancy ConsortiumNETWORK | 3 | Dec 17, 2025 | clinicaltrials |
| NCT04091022 | Topical Diclofenac and Topical DFMO Chemoprevention Trial in Subjects With a History of Skin Cancer | completed | Phase 2 | 64 | University of Alabama at BirminghamOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT03534947 | A Study to Evaluate Neoadjuvant Sonidegib Followed by Surgery or Imiquimod in the Management of Basal Cell Carcinoma(SONIB) | completed | Phase 2 | 16 | Melanoma Institute AustraliaOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT01950390 | Ipilimumab With or Without Bevacizumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 2 | 169 | National Cancer Institute (NCI)NIH | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04454489 | Quad Shot Radiotherapy in Combination With Immune Checkpoint Inhibition | completed | Phase 2 | 21 | Wake Forest University Health SciencesOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT04074746 | Modified Immune Cells (AFM13-NK) and A Monoclonal Antibody (AFM13) in Treating Patients With Recurrent or Refractory CD30 Positive Hodgkin or Non-Hodgkin Lymphomas | completed | Phase 1 / Phase 2 | 45 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT03695471 | Pembrolizumab in Treating Patients With Stage IB-IV Mycosis Fungoides | completed | Phase 2 | 9 | Mayo ClinicOTHER | 1 | Aug 29, 2025 | clinicaltrials |
| NCT05578872 | A Study of ANV419 Alone or in Combination With Approved Treatment in Patients With Cutaneous Melanoma (OMNIA-1). | completed | Phase 1 / Phase 2 | 29 | Anaveon AGINDUSTRY | 5 | Aug 26, 2025 | clinicaltrials |
| NCT06149247 | HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL | completed | Phase 2 | 10 | SoligenixINDUSTRY | 1 | Aug 20, 2025 | clinicaltrials |
| NCT04620200 | Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery(MATISSE) | completed | Phase 2 | 50 | The Netherlands Cancer InstituteOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT02836548 | HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma | completed | Phase 1 / Phase 2 | 33 | The Netherlands Cancer InstituteOTHER | 1 | Jul 10, 2025 | clinicaltrials |
| NCT00832429 | Lymph Node Mapping in Finding Metastatic Disease in Patients With Sebaceous Gland Cancer of the Eyelid | completed | Phase 2 | 20 | M.D. Anderson Cancer CenterOTHER | 1 | Jul 4, 2025 | clinicaltrials |
| NCT05188729 | Open-Label Proof of Concept Study of VP-315 in Basal Cell Carcinoma | completed | Phase 2 | 92 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Jun 18, 2025 | clinicaltrials |
| NCT02760498 | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 432 | Regeneron PharmaceuticalsINDUSTRY | 8 | May 28, 2025 | clinicaltrials |
| NCT03108131 | Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors | completed | Phase 2 | 49 | M.D. Anderson Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT05799157 | Safety and Efficacy of VDMN-21 Patch in Subjects With Common Warts | completed | Phase 2 | 153 | Veradermics, Inc.INDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT04339062 | Cemiplimab in AlloSCT/SOT Recipients With CSCC(CONTRAC) | completed | Phase 1 / Phase 2 | 12 | Dana-Farber Cancer InstituteOTHER | 1 | Apr 23, 2025 | clinicaltrials |
| NCT02875132 | Pembrolizumab in Advanced/Metastatic Acral Lentiginous Melanoma | completed | Phase 2 | 9 | Chinese University of Hong KongOTHER | 1 | Apr 18, 2025 | clinicaltrials |
| NCT00604890 | Dose-Ranging Clinical Trial of Topical Creams Containing API 31510 for the Treatment of Superficial Basal Cell Carcinoma | completed | Phase 1 / Phase 2 | 186 | BPGbioINDUSTRY | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04312841 | Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab | completed | Phase 2 | 6 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 28, 2025 | clinicaltrials |
| NCT04710498 | Neoadjuvant Atezolizumab in Surgically Resectable Advanced Cutaneous Squamous Cell Carcinoma | completed | Phase 2 | 20 | Stanford UniversityOTHER | 1 | Feb 3, 2025 | clinicaltrials |
| NCT02500576 | Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma | completed | Phase 2 | 18 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 15, 2025 | clinicaltrials |
| NCT01902173 | Uprosertib, Dabrafenib, and Trametinib in Treating Patients With Stage IIIC-IV Cancer | completed | Phase 1 / Phase 2 | 27 | National Cancer Institute (NCI)NIH | 1 | Jan 14, 2025 | clinicaltrials |
| NCT03033576 | Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma | completed | Phase 2 | 94 | National Cancer Institute (NCI)NIH | 1 | Jan 13, 2025 | clinicaltrials |
| NCT01973322 | Vaccination With Autologous Dendritic Cells Loaded With Autologous Tumor Lysate or Homogenate Combined With Immunomodulating Radiotherapy and/or Preleukapheresis IFN-alfa in Patients With Metastatic Melanoma: a Randomized "Proof-of-principle" Phase II Study(ABSIDE) | completed | Phase 2 | 34 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Jan 9, 2025 | clinicaltrials |
| NCT04470726 | Safety and Efficacy Evaluation of AIV001 in Nonmelanoma Skin Cancer of the Low Risk Basal Cell Carcinoma Subtype(NMSC) | completed | Phase 1 / Phase 2 | 26 | AiViva BioPharma, Inc.INDUSTRY | 1 | Dec 27, 2024 | clinicaltrials |
| NCT03487549 | Cantharidin and Occlusion in Verruca Epithelium(COVE-1) | completed | Phase 2 | 56 | Verrica Pharmaceuticals Inc.INDUSTRY | 1 | Nov 27, 2024 | clinicaltrials |
Data updated 22 days agoSource updated Sep 4, 2026source: clinicaltrials